Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group

European Journal of Cancer

Volumn 49, Issue 8, 2013, Pages 1905-1914

  Du Bois, Andreas ^a,b   Ewald Riegler, Nina ^b   De Gregorio, Nikolaus ^c   Reuss, Alexander ^d   Mahner, Sven ^e   Fotopoulou, Christina ^f   Kommoss, Friedrich ^g   Schmalfeldt, Barbara ^h   Hilpert, Felix ⁱ   Fehm, Tanja ^j   Burges, Alexander ^k   Meier, Werner ^l   Hillemanns, Peter ^m   Hanker, Lars ⁿ   Hasenburg, Annette ^o   Strauss, Hans Georg ^p   Hellriegel, Martin ^q   Wimberger, Pauline ^r   Keyver Paik, Mignon Denise ^s   Baumann, Klaus ^t   Canzler, Ulrich ^u   Wollschlaeger, Kerstin ^v   Forner, Dirk ^w   Pfisterer, Jacobus ^x   Schröder, Willibald ^y   Münstedt, Karsten ^z   Richter, Barbara ^aa   Kommoss, Stefan ^b,ab   Hauptmann, Steffen ^p   more..

^a KLINIKEN ESSEN MITTE   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g Institut fur Pathologie   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^j UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l Children s Hospital   (Germany)

^m HANNOVER MEDICAL SCHOOL   (Germany)

ⁿ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^o UNIVERSITY OF FREIBURG   (Germany)

^p MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^q UNIVERSITY OF GÖTTINGEN   (Germany)

^r UNIVERSITY HOSPITAL ESSEN   (Germany)

^s UNIVERSITY HOSPITAL BONN   (Germany)

^t UNIVERSITY HOSPITAL MARBURG   (Germany)

^u UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^v UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^w SANA KLINIKUM OFFENBACH   (Germany)

^x STÄDTISCHES KLINIKUM SOLINGEN   (Germany)

^y GYNAEKOLOGICUM Bremen   (Germany)

^z UNIVERSITY HOSPITAL GIESSEN   (Germany)

^aa Elblandkliniken Radebeul   (Germany)

^ab UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

Borderline tumours; Low malignant potential; Ovary; Prognosis; Staging; Surgery

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BORDERLINE OVARIAN TUMOR; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CYSTECTOMY; FEMALE; HISTOLOGY; HUMAN; LAPAROSCOPY; LAPAROTOMY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MULTIMODALITY CANCER THERAPY; OVARY CANCER; OVARY TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RISK ASSESSMENT; SALPINGOOOPHORECTOMY; SURGICAL APPROACH; TUMOR DIAGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); OVARIAN NEOPLASMS; OVARY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84876682999     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.01.035     Document Type: Article

References (35)

1. F.A. Tavassoli, and P. Devilee World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs 2003 IARC Press Lyon
2. A.P. Heintz, F. Odicino, and P. Maisonneuve Carcinoma of the ovary. FIGO sixth annual report on the results of treatment in gynecological cancer Int J Gynecol Obstet 95 Suppl. 1 2006 S161 S192
3. I. Skírnisdóttir, H. Garmo, and E. Wilander Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer Int J Cancer 123 2008 1897 1901
4. A. du Bois, N. Ewald-Riegler, and O. du Bois Borderline-tumoren des Ovars-eine systematische Übersicht Geburtsh Frauenheilk 69 2009 807 833
5. V. Beral, R. Doll, and C. Hermon Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls Lancet 371 2008 303 314
6. R.B. Ness, D.W. Cramer, and M.T. Goodmann Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies Am J Epidemiol 155 2002 217 224
7. O. Faluyi, M. Mackean, C. Gourley, A. Bryant, and H.O. Dickinson Interventions for the treatment of borderline ovarian tumours Cochrane Database Syst Rev 9 2010 10.1002/14651858.CD007696.pub2 Art. No.: CD007696
8. du Bois A, Burges A, Emons G, et al. Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren. Kommission Ovar der AGO e.V., Hrsg. Schmalfeldt B, Pfisterer J. München: W. Zuckschwerdt Verlag; 2007.
9. J.D. Seidman, and R.J. Kurman Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators Hum Pathol 31 2000 539 557
10. E.G. Silva, D.M. Gershenson, A. Malpica, and M. Deavers The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent Am J Surg Pathol 30 2006 1367 1371
11. B.H. Ortiz, M. Ailawadi, and C. Colitti Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors Cancer Res 61 2001 7264 7267
12. R.E. Emerson, M. Wang, and F. Liu Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions Int J Gynecol Pathol 26 2007 387 394
13. J. Gu, L.M. Roth, and C. Younger Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential J Natl Cancer Inst 93 2001 1147 1152
14. R.J. Kurman, and I.-M. Shih Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications Int J Gynecol Pathol 27 2008 151 160
15. C.N. Landen Jr., M.J. Birrer, and A.K. Sood Early events in the pathogenesis of epithelial ovarian cancer J Clin Oncol 26 2008 995 1005
16. K. Levanon, C. Crum, and R. Drapkin New insights into the pathogenesis of serous ovarian cancer and its clinical impact J Clin Oncol 26 2008 1 10
17. M. Cusido, L. Balaguero, and G. Hernandez Results of the national survey of borderline ovarian tumors in Spain Gynecol Oncol 104 2007 617 622
18. R. Fauvet, J. Boccara, C. Dufournet, C. Poncelet, and E. Darai Laparoscopic management of borderline ovarian tumors: results of a French multicenter study Ann Oncol 16 2005 403 410
19. Y. Yokoyama, T. Moriya, and T. Takano Clinical outcome and risk factors for recurrence in borderline ovarian tumours Br J Cancer 94 2006 1586 1591
20. D.M. Gershenson, E.G. Silva, and G. Tortolero-Luna Serous borderline tumors of ovarian with noninvasive peritoneal implants Cancer 83 1998 2157 2163
21. D.M. Gershenson, E.G. Silva, and L. Levy Ovarian serous borderline tumors with invasive peritoneal implants Cancer 82 1998 1096 1103
22. R.E. Bristow, D.R. Gossett, and D.R. Shook Micropapillary serous ovarian carcinoma: surgical management and clinical outcome Gynecol Oncol 86 2002 163 170
23. A. du Bois, J. Rochon, J. Pfisterer, and W. Hoskins Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review Gynecol Oncol 112 2008 422 436
24. P.S. Lin, D.M. Gershenson, and M.W. Bevers The current status of surgical staging of ovarian serous borderline tumors Cancer 85 1999 905 911
25. T. Song, C.H. Choi, and T.J. Kim Accuracy of frozen section diagnosis of borderline ovarian tumors Gynecol Oncol 122 2011 127 131
26. K.K. Shih, K. Garg, and R.A. Soslow Accuracy of frozen section diagnosis of ovarian borderline tumor Gynecol Oncol 123 2011 517 521
27. R.T. Morris, D.M. Gershenson, and E.G. Silva Outcome and reproductive function after conservative surgery for borderline ovarian tumors Obstet Gynecol 95 2000 541 547
28. K.K. Shih, Q. Zhou, and J. Huh Risk factors for recurrence of ovarian borderline tumors Gynecol Oncol 120 2011 480 484
29. J.Y. Park, D.Y. Kim, and J.H. Kim Micropapillary pattern in serous borderline ovarian tumors: does it matter? Gynecol Oncol 123 2011 511 516
30. T.A. Longacre, J.K. McKenney, H.D. Tazelaar, R.L. Kempson, and M.R. Hendrickson Ovarian tumors of low malignant potential (borderline tumors) Am J Surg Pathol 29 2005 707 723
31. P. Morice, S. Camatte, and A. Rey Prognostic factors for patients with advanced stage serous borderline tumors of the ovary Ann Oncol 14 2003 592 598
32. S. Chafe, L. Honore, R. Pearcey, and V. Capstick An analysis of the impact of pathology review in gynecologic cancer Int J Radiat Oncol Biol Phys 48 2000 1433 1438
33. M.A. Khalifa, J. Dodge, A. Covens, R. Osborne, and I. Ackerman Slide review in gynecologic oncology ensures completeness of reporting and diagnostic accuracy Gynecol Oncol 90 2003 425 430
34. Y.M. Chan, A.N.Y. Cheung, and D.K.L. Cheng Pathology slide review in gynecologic oncology: routine or selective? Gynecol Oncol 75 1999 267 271
35. A. du Bois, J. Rochon, C. Lamparter, and J. Pfisterer Pattern of care and impact of participation in clinical trials on outcome in ovarian cancer Int J Gynecol Cancer 15 2005 183 191